When was iCardiac Technologies founded?

iCardiac Technologies was founded in 2006 and raised its 1st funding round within a year of its incorporation.

Where is iCardiac Technologies located?

iCardiac Technologies is headquartered in Rochester, United States.

How many employees does iCardiac Technologies have?

As of Jul 01, 2024, the latest employee count at iCardiac Technologies is 51 - 200.

Is iCardiac Technologies a funded company?

iCardiac Technologies is a funded company, having raised a total of $4M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 07, 2006.

When was the latest funding round of iCardiac Technologies?

iCardiac Technologies' latest funding was a $***** Series C round on Mar 06, 2014, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $678M in funding in 2026 to date.

Where does iCardiac Technologies rank among its competitors?

iCardiac Technologies ranks 7th amongst 99 active competitors, of which 7 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was MindBio Therapeutics, which secured an undisclosed amount in Apr, 2026.

Who are the top competitors of iCardiac Technologies?

iCardiac Technologies' top competitors include Celerion, Altasciences and BioPharma Services. Among them, MindBio Therapeutics secured the most recent funding round in April, 2026.

iCardiac Technologies - 2026 Company Profile, Funding & Competitors

Company Details

iCardiac Technologies is a dedicated ECG core laboratory for cardiac safety testing and respiratory services. Its iClinica platform maximises precision and accuracy of data analysis while decreasing the cost of cardiac safety assessments from First-in-Human studies to Phase III studies including Thorough QT (TQT) studies. The company claims to have introduced multiple breakthrough innovations to the cardiac safety industry, through their High Precision QT and Early Precision QT methodologies. The company claims to be serving 8 of the top 10 biopharma companies and also the numerous small and mid-sized pharma and biotech companies. The company acquired the clinical trials division nSpire Health in August 2015 to add respiratory and ePRO services to its portfolio.

Website: icardiac.com
Social

Key Metrics

Founded Year

2006

Location

Rochester, United States

Stage

Acquired

Total Funding

$4M in 3 rounds

Latest Funding Round

Series C, Mar 06, 2014, $*****

Investors

Norwest & 5 more

Ranked

7^th among 99 active competitors

Employee Count

51 - 200 as on Jul 01, 2024

Similar Companies

Celerion & 119 more

Exit Details

Acquired by Clario (Dec 04, 2017)

View iCardiac Technologies' full profile

iCardiac Technologies got acquired by Clario on Dec 04, 2017.

Click here to take a look at iCardiac Technologies's acquisition in detail

iCardiac Technologies has raised a total funding of $4M over 3 rounds. Its first funding round was on Nov 07, 2006. Its latest funding round was a Series C round on Mar 06, 2014 for $*****. 1 investor participated in its latest round. iCardiac Technologies has 6 institutional investors.

Here is the list of recent funding rounds of iCardiac Technologies:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 06, 2014	1023898	Series C	3908844	4622701	1070234	4732192
Nov 13, 2007	2605223	Series B	2656476	9147646	7784351	Advantage Capital & 2 more
Nov 07, 2006	3988396	Series A	6307167	3869393	5355405	Advantage Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of iCardiac Technologies's funding rounds and investors

iCardiac Technologies' employee count trend

iCardiac Technologies has 51 - 200 employees as of Jul 24. Here is iCardiac Technologies's employee count trend over the years:

Employee count trend for iCardiac Technologies

Uncover iCardiac Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of iCardiac Technologies include Celerion, Altasciences and BioPharma Services. Here is the list of Top 10 competitors of iCardiac Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Celerion 2010, Lincoln (United States), Acquired	Translational medicine experts accelerating drug development for global patient impact	-	H.I.G. Private Equity, H.I.G. Capital & 7 others	51/100
2nd	Altasciences 2015, Laval (Canada), Acquired	Early phase CRO	-	Apollo Investment Corporation, Signet Healthcare Partners ... & 1 others	50/100
3rd	BioPharma Services 2006, Toronto (Canada), Acquired	Provider of early stage clinical trial services	-	-	48/100
4th	MindBio Therapeutics 2021, Melbourne (Australia), Public	Provider of phase I & II clinical trial services for mental health diseases	-	Blackhawk Growth Corp, Hardenbrook Group	44/100
5th	Avance Clinical 2018, Thebarton (Australia), Late Stage	Provider of clinical development services	-	Riverside, Genesis Capital	43/100
6th	Aditum Bio 2019, Cambridge (United States), Unfunded	CRO focused on clinical trial on phase II studies	-	-	42/100
7th	iCardiac Technologies 2006, Rochester (United States), Acquired	Company offering core laboratory services mainly for cardiac safety testing and respiratory diseases	$4M	Norwest, Topmark Partners & 4 others	41/100
8th	Unravel Biosciences 2020, Boston (United States), Seed	CRO offering early stage clinical development of drugs	$500K	BoxOne Ventures, Beresford Ventures	40/100
9th	Ventura Biomed 2021, Germany, Unfunded	CRO offering early stage drug development services	-	-	40/100
10th	Biomind Labs 2005, Toronto (Canada), Public	Developer of novel pharmaceuticals targeting neurological disorders and related conditions	-	-	39/100